title: Liquid Biopsy for Cancer: Circulating Tumor Cells, Circulating Free DNA or Exosomes?
abstract: Precision medicine and personalized medicine are based on the development of biomarkers, and liquid biopsy has been reported to be able to detect biomarkers that carry information on tumor development and progression. Compared with traditional 'solid biopsy', which cannot always be performed to determine tumor dynamics, liquid biopsy has notable advantages in that it is a noninvasive modality that can provide diagnostic and prognostic information prior to treatment, during treatment and during progression. In this review, we describe the source, characteristics, technology for detection and current situation of circulating tumor cells, circulating free DNA and exosomes used for diagnosis, recurrence monitoring, prognosis assessment and medication planning.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Wenjie
authors.initials: W
authors.lastname: Xia
authors.forename: Zhengye
authors.initials: Z
authors.lastname: Lv
authors.forename: Chao
authors.initials: C
authors.lastname: Ni
authors.forename: Yin
authors.initials: Y
authors.lastname: Xin
authors.forename: Liu
authors.initials: L
authors.lastname: Yang
mesh_terms: D001706:Biopsy; D004247:DNA / Q000097:blood*; D055354:Exosomes / Q000378:metabolism*; D006801:Humans; D035683:MicroRNAs / Q000097:blood; D009369:Neoplasms / Q000097:blood / Q000175:diagnosis / Q000473:pathology*; D009360:Neoplastic Cells, Circulating / Q000378:metabolism* / Q000473:pathology; D011379:Prognosis
chemical_list: D035683:MicroRNAs; D004247:DNA
keywords: Circulating free DNA; Circulating tumor cells; Exosomes; Liquid biopsy